Vistagen Therapeutics, Inc.

Vistagen Therapeutics is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric and neurological disorders. The company's pipeline centers on pherine-based nasal spray formulations, which are synthetic compounds designed to modulate neural signaling. The most advanced candidate, Fasedienol, is in Phase III trials for social anxiety disorder under a collaboration with AffaMed Therapeutics. Additional programs in Phase II development include Itruvone for major depressive disorder, PH80 for vasomotor symptoms associated with menopause, PH15 for cognitive impairment, and PH284 for appetite loss and cachexia in chronic disease. The company also develops AV-101, an oral prodrug targeting N-methyl-D-aspartate receptors for depression and neurological conditions.

As a clinical-stage company, Vistagen generates no product revenue and operates primarily on capital raised for development activities. The company maintains a small operational footprint with approximately 59 full-time employees and is headquartered in South San Francisco, California. Founded in 1998 and incorporated in Nevada, the company is publicly traded on Nasdaq.